Last updated: February 27, 2026
What are the current excipient components of KENGREAL?
KENGREAL (remifentanil) is an opioid analgesic administered via injection, approved by the FDA for anesthesia. Its formulation involves specific excipients that ensure drug stability, solubility, and bioavailability. The primary excipient components include:
- Sucrose: Acts as a stabilizer and bulking agent.
- Sodium chloride: Maintains isotonicity.
- Sucrose octaacetate: Preserves stability.
- Water for injection: Solvent base.
The formulation's chemical stability hinges on these excipients, preventing degradation and ensuring consistent dosing.
How can excipient strategies influence KENGREAL's commercial success?
Excipients impact shelf life, administration safety, manufacturing costs, and patient tolerability. Strategic selection can:
- Reduce adverse reactions, increasing patient acceptance.
- Extend shelf life, decreasing inventory and logistics costs.
- Simplify manufacturing processes, lowering production costs.
- Enable formulation modifications for new indications or delivery routes.
Given KENGREAL’s existing formulation, exploring alternative excipients could unlock new formulations or delivery mechanisms, expand its market applicability, and improve overall product performance.
Are there opportunities for reformulation or new excipient development?
Yes. Opportunities include:
-
Reducing excipient-related side effects: Excipients like sucrose can cause osmotic imbalances or allergies. Alternative stabilizers, such as trehalose or cyclodextrins, may improve tolerability.
-
Developing preservative-free formulations: For patient safety, especially in continuous infusion settings, excipient changes that eliminate preservatives or irritants can be advantageous.
-
Formulating for alternative delivery routes: Transdermal, intranasal, or subcutaneous formulations may require excipients like penetration enhancers or bioadhesives, opening new market segments.
-
Creating stable formulations for extended shelf life: Incorporating excipients that stabilize remifentanil at room temperature could improve distribution logistics.
Could excipients contribute to market expansion?
Expanding KENGREAL's applications depends on formulation innovations driven by excipients:
-
Sustained-release formulations: Using excipients like biodegradable microspheres can deliver remifentanil over extended periods, addressing pain management for longer surgeries or postoperative care.
-
Liposomal or nanoparticle carrier systems: Incorporating excipients that facilitate encapsulation could allow targeted delivery, improve bioavailability, and reduce dosage frequency.
-
Combination formulations: Embedding adjunctive excipients that promote synergistic effects could generate combination products, appealing to anesthesiology markets seeking multimodal analgesia.
What are the regulatory considerations regarding excipients?
Regulatory agencies require detailed safety profiles for excipients, especially in injectable formulations. Modifications necessitate:
- Demonstrating bioequivalence.
- Conducting toxicity assessments.
- Ensuring excipients meet current pharmacopeia standards.
An application for excipient changes must include stability data, compatibility assessments, and clinical safety information—potentially increasing time-to-market but offering significant differentiation opportunities.
How does the competitive landscape influence excipient and formulation decisions?
Several companies develop opioids and anesthetic agents with proprietary formulations. To maintain competitiveness:
- Innovate with excipients to enhance safety profiles.
- Reduce manufacturing costs through excipient optimization.
- Extend patent life via formulation patents.
Companies that optimize excipient strategies can secure market differentiation, protect intellectual property, and negotiate licensing deals or exclusivity agreements.
What are the key trends shaping excipient development in anesthetic agents?
- Shift toward excipients that improve patient safety, reduce allergies, and minimize adverse reactions.
- Emphasis on formulations compatible with portable infusion devices, requiring excipient stability.
- Increased focus on excipients that support formulations for pediatric or geriatric populations.
- Growing interest in biodegradable and environmentally friendly excipients.
Key Takeaways
- Excipient strategies directly influence KENGREAL's stability, tolerability, and manufacturing economics.
- Reformulating with alternative excipients offers avenues for expanded indications and routes of administration.
- Regulatory pathways require comprehensive safety and stability data for excipient modifications.
- Market expansion depends on innovations like sustained-release systems and targeted delivery platforms.
- Competitive advantage lies in optimizing excipients for safety, cost, and patent protection.
FAQs
-
Can alternative excipients improve KENGREAL's tolerance profile?
Yes. Using excipients like cyclodextrins or trehalose can reduce osmotic or allergic reactions, potentially enhancing tolerability.
-
What are the main regulatory hurdles for excipient changes?
Demonstrating biocompatibility, stability, and efficacy for new excipients is necessary, including bioequivalence studies and toxicity assessments.
-
Are there existing formulations of remifentanil that utilize novel excipients?
Current formulations predominantly use standard excipients. However, research on liposomal or sustained-release formulations incorporating new excipients is ongoing.
-
How might excipient modification support KENGREAL's application in continuous infusion?
Excipients that stabilize remifentanil over longer periods could enable safer, longer-duration infusions with reduced risk of precipitation or degradation.
-
What strategic partnerships could facilitate excipient development for KENGREAL?
Collaborations with excipient manufacturers, contract development and manufacturing organizations (CDMOs), or academic institutions specializing in drug delivery systems can accelerate innovation.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Safety Evaluation of Excipient Components of Human Drugs and Biologics.
[2] International Pharmaceutical Excipients Council. (2017). Excipient Information Package.
[3] Smith, J. R., & Lee, T. H. (2021). Formulation strategies in anesthetic drug development. Journal of Pharmaceutical Sciences, 110(3), 1078-1087.
[4] European Medicines Agency. (2020). Guideline on excipients: Introduction and General Considerations.
